ArticleJournal of neuro-oncology2026
Epilepsy characteristics and outcomes in patients with pleomorphic xanthoastrocytomas.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPleomorphic xanthoastrocytomas (PXAs) are rare brain tumors frequently associated with tumor-related epilepsy. Few studies have analyzed epilepsy outcomes in relation to tumor characteristics, clinical features, or neurophysiologic findings in this patient population.
methodsThis is a retrospective study of 25 patients diagnosed with a PXA at a single institution between 2004 and 2025. Clinical, pathologic, demographic, and treatment data were reviewed to identify factors associated with seizure outcomes after surgical resection.
resultsMost patients (19/25, 76%) had tumor-related epilepsy with 13/19 (68.4%) presenting with seizure as the initial symptom. In retrospect, 6/19 (31.6%) patients had unrecognized focal seizures prior to the index presentation. After the first tumor resection prior to tumor recurrence, 15/19 (78.9%) patients were seizure free. At the most recent follow-up visit, 13/19 (68.4%) patients were seizure free. Seizure freedom at the most recent follow up was observed in 7/8 (87.5%) patients with ATRX loss compared with 1/5 (20%) without ATRX loss (p = 0.01). Of the patients with seizure recurrence, 5/6 (83.3%) had recurrence of tumor on MRI within 30 days of the breakthrough seizure (p = 0.003).
conclusionsMost patients with PXA-associated tumor-related epilepsy achieved seizure freedom after initial resection. Seizure recurrence was strongly associated with tumor recurrence at long-term follow up. ATRX loss was associated with seizure freedom at the most recent follow up, suggesting that tumor molecular features may help prognosticate epilepsy outcomes. Nearly one-third of patients had previously unrecognized focal seizures highlighting the importance of a detailed, anatomically guided seizure history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.